<DOC>
	<DOCNO>NCT02215538</DOCNO>
	<brief_summary>This study look effectiveness osmotic release oral system ( OROS ) methylphenidate ( Concerta ) treat attention deficit hyperactvity disorder ( ADHD ) adult . Concerta receive FDA approval childhood ADHD documentation effective adult ADHD . However trial explore effectiveness treat symptom part Diagnostic Statistical Manual-III ( DSM-III ) criterion . Subjects experience one screen visit one baseline visit . Those meet admission criterion enter double-blind phase . This involve two 4-week treatment period one involve use Concerta placebo pill . Subjects complete double-blind phase allow enter 180-day , open-label Concerta phase design ass long-term effect .</brief_summary>
	<brief_title>OROS Methylphenidate ( Concerta ) Treatment Adult ADHD</brief_title>
	<detailed_description>ADHD affect 3 5 % child , persist adolescence 40 70 % child continue adulthood least 50 % affected adolescent . Pharmacotherapy ADHD adult parallel used child , generally positive result ( Spencer , 1998 ) . Never-the-less , clear dimension medication response adult child . The extent symptom change age remain open question . This trial create include variety outcome measure enhance number symptom assess . Methylphenidate first medication show effective treatment adult ADHD continue widely use . Several study demonstrate usefulness methylphenidate adult ADHD ( Wender et al , 1985 , Spencer et al , 1995 ) . These study show unexpected drawback treatment methylphenidate . The extended release formulation represent improvement immediate release version many patient . This double-blind , placebo-controlled , randomize , crossover trial compare OROS methylphenidate placebo . The double-blind trial precede enrollment period consist screen visit follow baseline visit . Patients continue meet admission criterion baseline randomize first two 4-week treatment period . We attempt reach high tolerate dose size within 2 week observe response last two week crossover phase . The double-blind period follow 180 day open-treatment , flexible-dose phase design ass long-term effect .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Adults meet DSMIVText Revision criterion ADHD , Utah Criteria ADHD , experience least moderate impairment ( score 4 great CGISeverity Scale ADHD Screening Baseline visit ) enrol . Other criterion include : 1 . Subjects age 18 65 , inclusive ; 2 . Female subject eligible enter participate study : She nonchildbearing potential ; male sexual partner surgically sterilize ; implant levonorgestrel , injectable progesterone , oral contraceptive ; intrauterine device ( IUD ) ; sexually inactive male partner . Or agree use double barrier method contraception ( combination physical chemical method ) negative urine pregnancy test screen interview . 3 . Subject must general good health determine medical history , ECG , analysis , judgment study physician , would confirm patient 's good health . 4 . Subjects must read write level sufficient provide write informed consent complete studyrelated material . 1 . Subjects current DSMIV Axis I Disorders include Current lifetime history psychosis , current bipolar disorder type I , current Major Depressive Disorder , Current Anxiety Disorder ( unless opinion clinic physician ADHD primary disorder cause disability see patient ) ; 2 . Subjects DSMIV Axis II diagnosis severe would suggest nonresponsiveness pharmacotherapy ADHD noncompliance protocol ; 3 . Subjects risk suicide risk harm others ; 4 . History Substance Dependence accord DSMIV criterion within 3 month screen ; 5 . Subjects currently abuse illegal drug alcohol exclude study ; 6 . Positive urine screen drug abuse screen patient significant history substance use still meet criterion 4 5 . Patients risk substance abuse give urine drug screen ; 7 . Subjects stimulant would represent risk history stimulant abuse , 8 . History uncontrolled hypertension significant cardiovascular disease ; 9 . Any known suspected significant medical psychiatric illness ( e.g. , hepatic renal insufficiency , pulmonary ( asthma , chronic obstructive pulmonary disease , etc ) , gastrointestinal , endocrine , neurological metabolic disturbance , judgment investigator , may impair interpretation study result constitute significant safety concern context clinical trial ; 10 . Medications , include health food supplement judge investigator likely central nervous system activity ( example , St John 's Wort , gingko leaf , melatonin ) , permit study . If subject take medication prior study entry , must 7 day washout period prior Visit 2 . We ask honest report medication consume visit . In event medication psychoactive property consume , patient counsel regard use prohibit medication ; 11 . Use medication consider acceptable clinical investigator medical monitor 7day period start study ( Day 1 ) ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>ADHD</keyword>
	<keyword>adult</keyword>
	<keyword>WRAADDS</keyword>
	<keyword>OROS MPH</keyword>
	<keyword>emotional dysregulation</keyword>
</DOC>